Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Open accessThe DOI matches its Crossref record; 340 of the 344 references it cites were found in a registry or an index.
Abstract
Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular complications, which represent the major cause of mortality. Despite effective treatment of established cardiovascular (CV) risk factors (dyslipidemia, hypertension, procoagulant state), there remains a significant amount of unexplained CV risk. Insulin resistance is associated with a cluster of cardiometabolic risk factors known collectively as the insulin resistance (metabolic) syndrome (IRS). Considerable evidence, reviewed herein, suggests that insulin resistance and the IRS contribute to this unexplained CV risk in patients with T2DM. Accordingly, CV outcome trials with pioglitazone have demonstrated that this insulin-sensitizing thiazolidinedione reduces CV events in high-risk patients with T2DM. In this review the roles of insulin resistance and the IRS in the development of atherosclerotic CV disease and the impact of the insulin-sensitizing agents and of other antihyperglycemic medications on CV outcomes are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, as the MAPK pathway has normal sensitivity to insulin, hyperinsulinemia activates the MAPK pathway, promoting vascular smooth muscle cell growth and activating inflammatory pathways, such as IkB/NF-kB and JNK [107,108].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [108]
In the citing paper
“These macrophages, in combination with adipocytes and lipid-infiltrated muscle tissues, stimulate the secretion of proinflammatory cytokines, particularly TNF-α and IL-6, while reducing the release of protective adiponectin, thereby evoking systemic chronic inflammation that directly damages the vascular endothelium and, in, turn exacerbates IR and atherosclerosis (56).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [56]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Research works printed but not linked: 1
- Hsueh, 1999, Insulin signals in the arterial wall, J Cardiol, 84, 21, 10.1016/S0002-9149(99)00353-7 · DOI · Paper page
Cited by
Items 201–300 of 535
Yang, Y., Ma, M., Zhang, J., Jin, S., Zhang, D., & Lin, X. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02037-6 · Cited by 9
Guan, Z., Stephan, B. C. M., Donini, L. M., Prado, C. M. M., Sim, M., & Siervo, M. (2024) · Proceedings of The Nutrition Society · doi:10.1017/s0029665124007559 · Cited by 14
“Furthermore, as SO progresses, fat accumulation can lead to the dysregulated production of adipokines and the infiltration of macrophages and other immune cells into adipose tissue (59) .”
Machine Learning-Driven Metabolic Syndrome Prediction: An International Cohort Validation Study
Zhao, L., Wenzhong, W., & Kang, H. (2024) · Healthcare · doi:10.3390/healthcare12242527 · Cited by 19
Feng, Q., Jiang, M., Peng, X., He, H., Jia, D., Feng, J., Zhang, Z., Xiong, S., & Cai, L. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02534-2 · Cited by 10
Zhu, B., Cao, C., Liu, W., Liu, Y., Luo, Y., & Peng, D. (2024) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2024.103182 · Cited by 10
Söner, S., Aktan, A., Kılıç, R., Güzel, H., Taştan, E., Okşul, M., Cömert, A. D., Coşkun, M. S., Söner, H. T., & Güzel, T. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04474-5 · Cited by 9
“This is because IR promotes the death of endothelial cells, vascular smooth muscle cells, and macrophages [33, 34].”
Zhu, Y. G., Yao, T., Li, T. X., Zhang, Y., & Ke, Q. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02652-5 · Cited by 14
Liu, D., Guan, X., Chen, R., Song, C., Qiu, S., Xu, S., Cao, J., & Liu, H. (2024) · Renal Failure · doi:10.1080/0886022x.2024.2320261 · Cited by 9
Pancreatic β-cell dysfunction in normoglycemic patients and risk factors
Vilchis-Flores, L. H., Barajas-Medina, G. A., Villa-Martínez, A., López, S. S. S., Luna-Patiño, G. A., Quiroz-Hernández, M. E., Guzmán-Vanegas, M. A., Rodríguez-Cortés, R., Angulo-Romero, F., Reyes‐Escogido, M. D. L., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01411-9 · Cited by 190
Metabolic syndrome in children
Tagi, V. M., Samvelyan, S., & Chiarelli, F. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05834-x · Cited by 9
Ghadieh, H. E., Helal, R. A., Muturi, H. T., Issa, D., Russo, L., Abdallah, S. L., Najjar, J. A., Benencia, F., Vázquez, G., Li, W., et al. (2020) · Hepatology Communications · doi:10.1002/hep4.1590 · Cited by 9
“(4) In addition to liver dysfunction, patients with NAFLD/NASH are at a higher risk of developing cardiovascular diseases, including atherosclerosis.(4-7) This has stimulated interest in identifying shared molecular mechanisms underlying cardiometabolic diseases.”
BackgroundChung, S. T., Matta, S. T., Meyers, A. G., Cravalho, C. K. L., VILLALOBOS-PEREZ, A., DAWSON, J. M., Sharma, V. R., Sampson, M. L., Otvos, J. D., & Magge, S. N. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.665292 · Cited by 9
Gycyrrhizic acid alleviates atherosclerotic lesions in rats with diabetes mellitus
Zhao, Y.-D., Li, W., & Zhang, D. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12395 · Cited by 11
“Numerous associations between DM and atherosclerosis (AS) have been identified, too much sugar in the blood is associated with insufficient insulin production or a reduced body response to insulin (6,7).”
BackgroundChen, A. X., & Burt, M. G. (2022) · Clinical Endocrinology · doi:10.1111/cen.14850 · Cited by 11
“synthesis of the vasodilator nitric oxide is reduced and atherogenesis enhanced.(72) In patients successfully treated for Cushing's syndrome, hypertension persists in 25%–40%.”
BackgroundPossible role of LCZ696 in atherosclerosis: new inroads and perspective
Al-Kuraishy, H. M., Al-Gareeb, A. I., Elekhnawy, E., & Batiha, G. E. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04816-x · Cited by 9
Fu, Y., Yuan, J., Sang, F., Shao, M., Yan, S., Li, L., Zhu, R., & Wang, Z. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/9131178 · Cited by 8
“Macrovascular complication is the main clinical outcome and primary cause of disability and mortality among diabetic individuals [1, 2].”
BackgroundGlucokinase activators and imeglimin: new weaponry in the armamentarium against type 2 diabetes
Sjöholm, Å. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004291 · Cited by 10
Wang, D., He, Q., Sun, W., Li, W., Yang, Y., Cui, W., & Yang, X. (2025) · Nutrients · doi:10.3390/nu17091462 · Cited by 11
Zeng, J., Li, N., Ma, C., Song, Y., Tian, W., Gao, Y., Tang, S., Liu, X., & Tian, X. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02769-2 · Cited by 8
Kim, H., Kim, B. S., Kim, H., Lee, J., Jo, H. H., Kim, D. W., Shin, J., & Sung, K. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2025.194 · Cited by 12
“Similarly, metabolic dysfunction leads to dyslipidemia and hyperglycemia, causing vascular injury and glomerular hy-perfiltration, thus creating a vicious cycle [27,28].”
Vorotnikov, A. V., Popov, D. V., & Makhnovskii, P. A. (2022) · Biochemistry (Moscow) · doi:10.1134/s0006297922090139 · Cited by 9
Nitric Oxide, Its Role in Diabetes Mellitus and Methods to Improve Endothelial Function
Nikolaeva, M., & Johnstone, M. T. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_7 · Cited by 13
Pan, J. H., Yang, B., Wang, Z., Tang, L., Jia, P., Yang, S., & Zeng, H. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s418358 · Cited by 8
Aortic Fibrosis in Insulin-Sensitive Mice with Endothelial Cell-Specific Deletion of Ceacam1 Gene
Helal, R. A., Muturi, H. T., Lee, A. D., Li, W., Ghadieh, H. E., & Najjar, S. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084335 · Cited by 7
“It also supports the observation that pioglitazone, an insulin sensitizer and a PPARγ agonist, ameliorates atherosclerosis in at risk patients [8].”
BackgroundResultThe role of adipose tissue-derived hydrogen sulfide in inhibiting atherosclerosis
Tian, Z., Deng, N.-H., Zhou, Z., Ren, Z., Xiong, W., & Jiang, Z. (2022) · Nitric Oxide · doi:10.1016/j.niox.2022.07.001 · Cited by 8
Genovesi, S., Montelisciani, L., Giussani, M., Lieti, G., Patti, I., Orlando, A., Antolini, L., & Parati, G. (2023) · Metabolites · doi:10.3390/metabo13030327 · Cited by 10
Sun, C., Gao, Y., Liang, Z., Liu, C., & Chen, M. (2024) · International Urology and Nephrology · doi:10.1007/s11255-024-03961-6 · Cited by 8
Maes, M. H. J., Jirakran, K., Semeão, L. D. O., Michelin, A. P., Matsumoto, A. K., Brinholi, F. F., Barbosa, D. S., Tivirachaisakul, C., Almulla, A. F., Stoyanov, D., et al. (2025) · medRxiv · doi:10.1101/2025.03.02.25323183 · Cited by 14
Wang, L., Hu, T., Li, R., Xu, L., Wang, Y., & Cheng, Q. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36826 · Cited by 8
Wu, T., Chou, C., Cheng, C.-F., Lu, S.-X., Wu, Y., & Wang, L. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01787-7 · Cited by 7
“Insulin resistance, which is an early preclinical stage of DM, induces several syndromes, including dyslipidemia, inflammation, hypertension, endothelial dysfunction, and vascular smooth muscle cell proliferation, which are correlated with the development of atherosclerosis [13].”
BackgroundPandey, M. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713223 · Cited by 7
Li, L., Cai, G., Lü, W., Li, F., Yu, L., & Xiao, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1255656 · Cited by 7
Ma, J., Wang, M., Wu, P., Ma, X., Chen, D., Jia, S., & Yan, N. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01306-y · Cited by 7
Fu, B., Zeng, Y., Wang, M., Zhao, L. Y., Sun, L., Wang, T., Dong, J., Yang, W., & Hua, W. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01423-8 · Cited by 7
“IR plays a key role in the pathogenesis of T2DM [21], obesity [22], metabolic syndrome [23], and atherosclerotic cardiovascular diseases (ASCVDs) [24].”
BackgroundThe Role of Glucose–Lymphocyte Ratio in Evaluating the Severity of Coronary Artery Disease
Serhatlıoğlu, F., Çetınkaya, Z., & Yılmaz, Y. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13226711 · Cited by 8
Dutt, C., Salles, J. E. N., Joshi, S., Nair, T., Chowdhury, S., Mithal, A., Mohan, V., Kasliwal, R. R., Sharma, S., Tijssen, J. G. P., et al. (2022) · DOAJ (DOAJ: Directory of Open Access Journals) · Cited by 7
Herance, J. R., Martín‐Saladich, Q., Velásquez, M. A., Hernández, C., Aparicio, C., Ramírez, C., Ferrer, R., Giralt, M., Ballester, M. Á. G., Pericàs, J. M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158783 · Cited by 7
Cheng, B., Yi, Y., Chen, M., Wei, Y., Su, X., Chen, P., Lin, X., Gu, Y., Li, T., Xu, C., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1383489 · Cited by 10
Al-Sabbagh, M. Q., Alsadi, H., Gurunathan, O. S., Eswaradass, P. V., & Thirunavukkarasu, S. (2025) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2025.109054 · Cited by 7
Tang, X.-E., Cheng, Y.-Q., & Tang, C. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1219690 · Cited by 6
Lee, J. H., Lee, H. S., Jeon, S., Lee, Y., Park, B., Lee, J., & Kwon, Y. (2023) · Endocrine · doi:10.1007/s12020-023-03615-0 · Cited by 6
Sastre-Alzamora, T., López, P. J. T., López‐González, Á. A., Vallejos, D., Paublini, H., & Ramírez‐Manent, J. I. (2024) · Diagnostics · doi:10.3390/diagnostics14212388 · Cited by 8
Cheng, Y., Du, X., Zhang, B., & Zhang, J. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1474-8220 · Cited by 6
Diabetes mellitus and heart failure — a modern look at the mechanisms of development
Svarovskaya, A. V., & Анатольевна, Г. А. (2022) · Diabetes Mellitus · doi:10.14341/dm12648 · Cited by 9
Zhong, X., Jiao, H., Zhao, D., Yang, M., & Teng, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1021267 · Cited by 6
Omar, N., Yeoh, B. S., Chellappan, K., Chui, S. Z., Salamt, N., & Aminuddin, A. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1062751 · Cited by 6
Qu, X., Wu, Y., Shen, L., Wang, C., Gao, L., Ma, J.-Q., Qu, Y., & Liu, B. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.107563 · Cited by 6
He, Y., Guan, X., Zhang, Y., Zhu, Z., Zhang, Y., Feng, Y., & Li, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2348562 · Cited by 8
“This is mainly due to the buildup of cholesterol in the arterial walls, which narrows and hardens them, thus reducing blood flow to the heart and other organs and resulting in life-threatening situations [5–7].”
Predicting Skeletal Muscle and Whole-Body Insulin Sensitivity Using NMR-Metabolomic Profiling
Klén, R., Honka, M., Hannukainen, J. C., Huovinen, V., Bucci, M., Latva‐Rasku, A., Venäläinen, M. S., Kalliokoski, K. K., Virtanen, K. A., Läutamaki, R., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa026 · Cited by 6
Zhao, Q., Cheng, Y., Xu, Y.-K., Zhao, Z.-W., Liu, C., Sun, T., & Zhou, Y.-J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.735637 · Cited by 8
Martínez‐Sánchez, F. D., Diaz-Jarquin, A., Vargas-Abonce, V. P., Torres-Cuevas, J. L., Guerrero-Castillo, A. P., Medina‐Julio, D., Meza-Arana, C. E., Gulías-Herrero, A., & Gómez-Sámano, M. Á. (2022) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2022.100091 · Cited by 10
Mousa, R., Smesam, H. N., Qazmooz, H. A., Hakeim, H. K. A., & Maes, M. (2020) · Preprints.org · doi:10.20944/preprints202009.0053.v1 · Cited by 6
Alogaili, M. H., & Alsallami, A. A. (2024) · Intern J Endocrinol Metab · doi:10.5812/ijem-145894 · Cited by 6
Shi, Y., Zhang, Z., Yang, J., & Cui, S. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1583944 · Cited by 5
Guo, Y., Cui, L., Guo, J., Jin, C., Xiu, L., Gao, Y., Zhao, C., Xu, X., Tan, J., Han, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1665292 · Cited by 6
“Insulin resistance (IR) is known to be one of the major risk factors for atherosclerosis, and is strongly linked to the occurrence and development of cardiovascular disease (CVD) (3, 4).”
Zhong, J., Liu, D., Huang, X., Yuan, J., Hong, Y., Xuan, W., Chen, W., Zhang, X., & He, L. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02774-5 · Cited by 8
Lai, J., Zhang, X., He, Y., & Liang, S. (2025) · Medicine · doi:10.1097/md.0000000000042562 · Cited by 10
“[7,8] The prevailing gold standard for evaluating IR is the hyper-insulinemic–euglycemic clamp and the homeostasis model assessment of insulin resistance (HOMA-IR).”
Zhang, J., Wu, D., Cheng, C., Yang, Z., Chen, Z., Liu, L., Li, W., Wang, W., Huang, C., & Yang, J. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112223 · Cited by 7
AbuHaweeleh, M. N., Ali, S., Elsalakawi, Y., Al-Khulaifi, A. A., Maggio, V., Rizzo, M., & Boudaka, A. (2026) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2026.1759605 · Cited by 9
Liu, C., Zhao, Q., Ma, X., Cheng, Y., Sun, Y., Zhang, D., Liu, X., & Zhou, Y. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2401002 · Cited by 6
“WC, which reflects visceral fat, is strongly correlated with IR and atherosclerotic cardiovascular disease (ASCVD) progression [39].”
BackgroundWang, Z., Wan, Q., Xie, B., Zhu, Z., Xu, X., Fu, P., & Liu, R. (2023) · Molecular Omics · doi:10.1039/d3mo00067b · Cited by 6
Enhanced Outcomes in Type 2 Diabetes Patients With Acute Kidney Disease Through Thiazolidinedione
Chang, L., Liao, H., Chen, J., & Wu, V. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae796 · Cited by 8
Chen, Y., Zheng, L., Zhou, Y., Hou, Y., Zhou, Y., & Shen, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-00359-x · Cited by 5
“First, eGDR serves as a reliable marker for IR, which promotes atherosclerosis, potentially resulting in renal artery stenosis or occlusion, ultimately contributing to CKD events 46–48 .”
Liu, Q., Yang, M., Zhang, L., Zhang, R., Huang, X., Wang, X., Du, W., & Hou, J. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12348 · Cited by 6
“In recent years, extensive clinical studies have confirmed the close relationship between diabetes mellitus or impaired glucose tolerance and AS (33,34).”
BackgroundMurai, N., Saito, N., Nii, S., Nishikawa, Y., Suzuki, A., Kodama, E., Iida, T., Mikura, K., Imai, H., Hashizume, M., et al. (2021) · Hypertension Research · doi:10.1038/s41440-021-00749-4 · Cited by 5
Şaylık, F., & Akbulut, T. (2022) · Acta cardiologica. Supplementum · doi:10.1080/00015385.2022.2106017 · Cited by 5
Metabolic/bariatric surgery protects against cardiovascular disease
Mingrone, G., Castagneto‐Gissey, L., & Bornstein, S. R. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac069 · Cited by 6
Das, D., Jothimani, G., Banerjee, A., Duttaroy, A. K., & Pathak, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117607 · Cited by 5
Zahedi, M., Das, S., Dabla, P. K., & Kandar, S. (2025) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2025.108672 · Cited by 4
Liu, M., Liu, F., Diljhumal, A., Yang, J., Wang, Y., Ye, M., Jia, T., & Gao, Y. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1629294 · Cited by 4
Soleimani, A., Maghsoodi, M., Bahrani, S., Amerizadeh, A., & Teimouri-Jervekani, Z. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04646-3 · Cited by 5
Correlation between triglyceride glucose index and coronary plaque: An observational study
Jia, H.-Y., Zhang, W.-F., Jia, S.-Q., Zhang, J., Xu, Z.-S., Xu, Z.-W., & Li, Y. (2024) · Medicine · doi:10.1097/md.0000000000039576 · Cited by 4
“[18] Chen et al [19] used Mendelian randomization analysis to find a causal relationship between insulin resistance and the risk of coronary artery disease, myocardial infarction and ischemic stroke, providing genetic evidence to support that insulin resistance may lead to an increased risk of…”
BackgroundMethodHou, Y., Guo, X., Yang, H., Li, H., Chen, R., Min, X., & Yu, J. (2025) · European journal of medical research · doi:10.1186/s40001-025-02629-w · Cited by 4
Cardiovascular benefits of GLP-1RA and SGLT-2i in women with type 2 diabetes
Mishriky, B. M., Cummings, D. M., & Powell, J. R. (2022) · Primary care diabetes · doi:10.1016/j.pcd.2022.03.012 · Cited by 5
Cellular and molecular mechanisms involved in metabolic disorders
Singh, L., & Bhatti, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99616-7.00015-3 · Cited by 5
MiR-143-3p/FNDC5 axis: a novel regulator of insulin sensitivity
Li, B., Dong, Y., Hu, S., & Liu, T. (2023) · Endocrine · doi:10.1007/s12020-023-03522-4 · Cited by 4
“A large number of previous studies have shown that chronic hyperglycemia and hyperinsulinemia are important inducers of insulin resistance [33, 34].”
Qin, X., Xie, Z., Chen, X., Wang, X., & Ma, L. (2023) · Medicine · doi:10.1097/md.0000000000035734 · Cited by 5
“[59,60] Our analysis showed multiple targets of Goji berries involved in atherosclerotic pathways (Fig.”
BackgroundLi, G., Yang, W., Kuang, Z., Cai, Y., & You, J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112263 · Cited by 5
Yang, D., Li, W., Luo, W., Yang, Y., Yi, J., Li, C., Gao, H., & Zhao, X. (2025) · Medicina · doi:10.3390/medicina61061064 · Cited by 4
Al-Shami, A. S., Alzumor, M., Al-Adhal, A., & Al-Saban, A. M. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01972-7 · Cited by 9
Zhu, Z., Wang, M., Chen, A., Lu, S., Dai, S., Liu, R., & Liu, J. (2025) · Medicine · doi:10.1097/md.0000000000045478 · Cited by 4
“[3] With rising global rates of obesity and diabetes, exploring the association mechanism between IR-related indexes and ASCVD has become an important scientific proposition for early prevention.”
Li, Q., Gong, L., & Li, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02018-7 · Cited by 3
Zou, X., Zhang, F., He, C., Zhang, W., Tang, R., Zhu, J., Ma, J., Li, Y., Wang, L., Cai, C., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02991-3 · Cited by 3
“The consistency of this combined effect across subgroups—including age, sex, BMI, smoking, and lipid levels—further highlights its generalizability, with heart disease being the only notable modifier of effect (P-inter-action 0.05) [39].”
InfluentialCho, J., Kim, T. H., Son, Y., Yim, Y., Oh, J., Kim, H., Jeong, J., Oh, J., Lee, S., Jacob, L., et al. (2025) · Medicine · doi:10.1097/md.0000000000045960 · Cited by 4
Hu, Y., Xu, L., Wang, X., Zhou, Z., Yang, W., Yuan, Y., Li, J., Qiu, S., Wang, Y., Wang, X., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1657186 · Cited by 3
Sun, Y., Huang, J., Yu, X., Meng, J., & Qiu, G. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1809007 · Cited by 3
“According to Di Pino ’ s review (7), IR has an “ independent and interactive ” relationship with atherosclerosis.”
Hasimun, P., Kusriani, H., Mulyani, Y., & Syaumi, N. (2024) · Journal of Herbmed Pharmacology · doi:10.34172/jhp.2024.51457 · Cited by 3
“Insulin resistance, often associated with hyperglycemia, can affect lipid metabolism, resulting in a higher atherogenic index by increasing triglycerides and decreasing high density lipoprotein (HDL) cholesterol (2,3).”
BackgroundDaoussi, N., Zemni, I., Gouta, N., Saad, Y., Dhia, R. B., Mhiri, M., Sriha, A. B., & Frih-Ayed, M. (2025) · Biomarkers in Medicine · doi:10.1080/17520363.2024.2443382 · Cited by 4
Stolfo, G. D., Mastroianno, M., Pacilli, M. A., Luca, G. D., Coli, C., Bevere, E. M. L., Pacilli, G., Potenza, D. R., & Mastroianno, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030815 · Cited by 4
Wang, L., Zhang, Y., Ji, F., Si, Z., Liu, C., Wu, X., Wang, C., & Chang, H. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70014 · Cited by 6
Lin, T., Jin, S., Shen, X., Huang, S., & Mao, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1525573 · Cited by 7
Henry, A. Z. V., Avogbe, P. H., & Sanni, A. (2025) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2025.139026 · Cited by 3
Liu, R., Li, J., Sun, Z., Zhou, T., Zhao, C., Tian, Q., Guo, J.-J., & Xuan, C. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2564277 · Cited by 5
“Alternatively, the Triglyceride-Glucose (TyG) index, derived from fasting triglyceride and glucose levels, has emerged as a simple and cost-effective tool for estimating IR [5,6].”
Zhao, W., Chen, L., Lin, Y., He, H., Ma, H., Hu, Q., Yang, W., Gao, F., & Chen, X. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2021.0119 · Cited by 4
As, A., P'yanykh, O. P., & Vovk, P. S. (2022) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2022-11-2-56-63 · Cited by 4
Garcés-Hernández, M. J., Pedraza-Escudero, K., Garibay-Nieto, N., Hernández-Ruiz, J., Prieto‐Chávez, J. L., Arriaga‐Pizano, L., Villanueva-Ortega, E., Escobedo, G., Manjarrez‐Reyna, A. N., López-Alvarenga, J. C., et al. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9100330 · Cited by 5
Li, Z., Mao, X., Cui, X., Yu, T., Zhang, M., Li, X., & Li, G. (2022) · Medicine · doi:10.1097/md.0000000000030738 · Cited by 3
Eid, M., Sayed, S. A., Zaki, N. A., Hamdy, A. M. F., & Altaher, A. M. (2023) · PubMed Central · doi:10.22088/cjim.14.3.495 · Cited by 7
“Pathology was declared when the HOMA-IR values fell below the 75 percentile (31).”
BackgroundLin, J., Dong, L., Huang, Q., Xiao, H., Li, S., Tang, J., Mao, X., Huang, P., Li, X., & Hong, D. (2024) · Brain and Behavior · doi:10.1002/brb3.3453 · Cited by 3
The Use of Fast-Acting Insulin Topical Solution on Skin to Promote Surgical Wound Healing in Cats
Carreira, L. M., Silva, R., Alves, J. C., Inácio, F., Alexandre‐Pires, G., & Azevedo, P. (2024) · Animals · doi:10.3390/ani14091358 · Cited by 3
“Additionally, insulin can modulate the activity of melanocytes, the pigment-producing cells in the skin, potentially leading to alterations in skin pigmentation [55].”
Background
Metadata
- Authors
- Di Pino, A., & DeFronzo, R. A.
- Affiliations
- Diabetes Division, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A
- ORCID
- DeFronzo, Ralph A
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2019-05-03
- Volume
- 40
- Issue
- 6
- Pages
- 1447-1467
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7445419
- OpenAlex
- W2945554427
- Cited by
- 535
- References
- 344
- Citations by year
- 2026: 77 · 2025: 117 · 2024: 95 · 2023: 76 · 2022: 89 · 2021: 55 · 2020: 22 · 2019: 4
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (DK-24092-38)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin resistance, atherosclerosis, type 2 diabetes, metabolic syndrome, insulin sensitizers, thiazolidinediones, pioglitazone, cardiovascular risk, macrovascular complications, cardiovascular outcome trials, antihyperglycemic medications, cardiometabolic risk factors
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Thiazolidinediones, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.